1. bookVolume 35 (2022): Issue 2 (August 2022)
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
access type Open Access

The recent guidelines for pharmacotherapy of Parkinson’s Disease

Published Online: 02 Sep 2022
Volume & Issue: Volume 35 (2022) - Issue 2 (August 2022)
Page range: 80 - 85
Received: 05 Mar 2022
Accepted: 10 Jun 2022
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
Abstract

Parkinson’s Disease (PD) is one of the most frequent disorders of the central nervous system (CNS). PD is an age-related disease in that morbidity increases with age. The main symptoms of it are motor symptoms like bradykinesia, rigidity and resting tremor. These symptoms diminish the comfort of the patient’s life and may lead to immobility. Hence, rapid diagnosis and start of treatment are very important.

The pharmacotherapy of PD is difficult. PD involves an imbalance between the dopaminergic and cholinergic systems. Therefore, the mechanisms of action of currently available drugs are highly connected with the pathology of PD, and follow dopaminergic or anticholinergic control strategies. However, long-term use of many PD medications comes with serious side effects. Therefore, the search for new, more effective drugs involving different strategies to that current and having different targets is still on-going.

Keywords

1. Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye A, et al. Chronic pain treatment strategies in Parkinson’s disease. Neurol Int. 2020;12(3):61-76.10.3390/neurolint12030014776853033218135 Search in Google Scholar

2. Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India. 2018;66(Suppl S1):26-35.10.4103/0028-3886.22645129503325 Search in Google Scholar

3. Pena-DIaz S, Ventura S. One ring is sufficient to inhibit α-synuclein aggregation. Neural Regen Res. 2022;17(3):508-11.10.4103/1673-5374.320973850437834380879 Search in Google Scholar

4. Chagraoui A, Boulain M, Juvin L, Anouar Y, Barrière G, Deurwaerdère PD. L-DOPA in Parkinson’s disease: Looking at the “False” neurotransmitters and their meaning. Int J Mol Sci. 2020;21(1):294.10.3390/ijms21010294698163031906250 Search in Google Scholar

5. Alborghetti M, Nicoletti F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr Neuropharmacol. 2019;17(9):861-73.10.2174/1570159X16666180830100754705284130160213 Search in Google Scholar

6. Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: A bayesian network meta-analysis. Front Neurol. 2021;12:707723.10.3389/fneur.2021.707723849775134630283 Search in Google Scholar

7. Li BD, Bi ZY, Liu JF, Si WJ, Shi QQ, Xue LP, at al. Adverse effects produced by different drugs used in the treatment of Parkinson’s disease: A mixed treatment comparison. CNS Neurosci Ther. 2017;23(10):827-42.10.1111/cns.12727649275728872217 Search in Google Scholar

8. Mao Q, Qin WZ, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin. 2020;41(4):471-82.10.1038/s41401-020-0365-y747147232112042 Search in Google Scholar

9. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905-18.10.1007/s40263-019-00661-z677656331473980 Search in Google Scholar

10. https://go.drugbank.com/ (access:11.05.2022) Search in Google Scholar

11. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson’s Disease. F1000research. 2020;9:F1000 Faculty Rev-862.10.12688/f1000research.25634.1740068332789002 Search in Google Scholar

12. Ghossein N, Kang M, Lakhkar AD. Anticholinergic medications. In: StatPearls [Internet]. Treasure Island (FL); 2021. Search in Google Scholar

13. Sharma VD, Lyons KE, Pahwa R. Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease. Ther Clin Risk Manag. 2018;14:665-73.10.2147/TCRM.S144481590549529695911 Search in Google Scholar

14. https://clinicaltrials.gov/ (access:11.05.2022) Search in Google Scholar

15. Yang L, Wang H, Liu L, Xie A. The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73.10.3389/fnins.2018.00073582621729515352 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo